Cover Image
市場調查報告書

憂鬱症性障礙的全球市場:產業分析與未來展望

Global Depressive Disorder Market: Industry Analysis & Outlook 2016-2020

出版商 Koncept Analytics 商品編碼 366844
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
憂鬱症性障礙的全球市場:產業分析與未來展望 Global Depressive Disorder Market: Industry Analysis & Outlook 2016-2020
出版日期: 2016年08月16日 內容資訊: 英文 57 Pages
簡介

本報告提供全球憂鬱症性障礙治療藥的市場相關分析,疾病的症狀和治療方法,市場規模趨勢預測 (患者數、市場收益額),主要的與推動及阻礙市場要素,主要的治療藥以及市場規模,主要企業簡介等相關調查。

第1章 市場概要

  • 簡介
  • 疾病的種類
  • 疾病的原因、症狀
  • 診斷、治療方法

第2章 全球市場

  • 全球憂鬱症性障礙的市場規模
  • 全球憂鬱症性障礙的市場規模的預測
  • 全球憂鬱症性障礙的市場規模:各地區
  • 全球抗憂鬱劑的市場規模
  • 全球抗憂鬱劑的市場規模的預測
  • 全球抗精神病藥的市場規模
  • 全球抗精神病藥的市場規模的預測

第3章 各地區市場

  • 美國
    • 憂鬱症性障礙的市場規模的預測
    • 精神病的處方數量
    • 憂鬱症性障礙的患病人數的預測
    • 躁鬱症的患病人數的預測
    • 躁鬱症的潛在的患者數
    • 思覺失調症的患病人數的預測
    • 思覺失調症的潛在的患者數
  • 歐洲
    • 憂鬱症性障礙的市場規模的預測
    • 躁鬱症的患病人數的預測
    • 躁鬱症的潛在的患者數
    • 思覺失調症的患病人數的預測
    • 思覺失調症的潛在的患者數
  • 中國
    • 躁鬱症的患病人數的預測
    • 躁鬱症的潛在的患者數
    • 思覺失調症的患病人數的預測
    • 思覺失調症的潛在的患者數

第4章 市場動態

  • 市場主要趨勢和動靜
    • 新藥的認證
    • 現在開發中的速效性的抗憂鬱劑
    • 給客戶的直接性廣告
    • 一般的認知度的上升
  • 推動市場成長要素
    • 處方藥的銷售額的增加
    • 醫藥品的支出額的增加
    • 吸煙者的增加
    • 公共衛生計劃的支出額的增額
    • 全球規模的醫療費的擴大
    • 全球規模的女性患者的增加
  • 市場課題
    • 專利到期
    • 嚴格的藥物法規
    • 嚴重的副作用

第5章 競爭環境

  • 全球憂鬱症性障礙的市場
    • 市場收益額比較
  • 全球抗憂鬱劑市場
    • 市場佔有率比較
    • 市場收益額比較
    • 產品比較
  • 全球抗精神病藥市場
    • 市場佔有率比較
    • 市場收益額比較
    • 產品比較

第6章 企業簡介

  • Pfizer Inc.
    • 產業概要
    • 主要的財務指標
    • 產業策略
  • AstraZeneca
  • Eli Lilly and Company
  • Lundbeck

圖表一覽

目錄

Depression is a serious mood disorder, affecting the ability to think, feel, and handle situations like sleeping, eating, or working. It is a mood disorder that causes a persistent feeling of sadness and loss of interest. It builds up a very negative perspective in the way of thinking in every single thing and damages a person's ability to see brighter versions of any situation in life. It is of various types like major depressive disorder (MDD), perinatal depression, psychotic depression, seasonal depression and bipolar depression.

To be diagnosed with depression, the symptoms must be present for at least two weeks. It may require long-term treatment for years. There is no single cause of depression; it is likely an outcome from combinations of genetic, biochemical, environmental and physiological factors. There are several ways of treating depression depending upon each individual's characteristics & symptoms. Most people feel better with medication, psychological counseling or both.

The global depressive disorder market is expected to grow and overcome falling revenues due to patent expiry with better innovative drugs and therapies. The US has highest depression disorder prevalence along with highest prevalence of bipolar depression & schizophrenia. With growing awareness and better access to medical facilities, the depressive disorder market is expected to grow worldwide, especially in Asia-Pacific region.

The key factors driving the growth of the depressive disorder market includes increased smoking prevalence, rising healthcare expenditure, growing female population, increasing spending on medicines and rising number of prescription drugs. However, there are certain factors hindering the growth of the market like patent expiry, severe side effects of drugs, and tough regulations. Major trends of the market include novel drug approvals, major drugs in pipeline, and growing public awareness.

The report offers an in-depth analysis of the “Global Depressive Disorder Market” segmented into global and regional markets. Competition is concentrated in the hands of few major pharmaceutical companies out of which Pfizer Inc., AstraZeneca, Eli Lilly and company, and Lundbeck have been covered in the report.

Table of Contents

1. Market Overview

  • 1.1. Introduction
  • 1.2. Types
  • 1.3. Causes & Symptoms
  • 1.4. Diagnosis & Treatment

2. Global Market

  • 2.1. Global Depressive Disorder Market by Value
  • 2.2. Global Depressive Disorder Market Forecast by Value
  • 2.3. Global Depressive Disorder Market by Region
  • 2.4. Global Anti-Depressant Drug Market by Value
  • 2.5. Global Anti-Depressant Drug Market Forecast by Value
  • 2.6. Global Anti-Psychotic Drug Market by Value
  • 2.7. Global Anti-Psychotic Drug Market Forecast by Value

3. Regional Markets

  • 3.1. The US
    • 3.1.1. The US Depressive Disorder Market Forecast by Value
    • 3.1.2. The US Mental Health Drug Prescription by Volume
    • 3.1.3. The US Depressive Disorder Patient Prevalence Forecast
    • 3.1.4. The US Bipolar Depression Patient Prevalence Forecast
    • 3.1.5. The US Bipolar Depression Addressable Population Forecast
    • 3.1.6. The US Schizophrenia Patient Prevalence Forecast
    • 3.1.7. The US Schizophrenia Addressable Population Forecast
  • 3.2. Europe
    • 3.2.1. European Depressive Disorder Market Forecast by Value
    • 3.2.2. European Bipolar Depression Patient Prevalence Forecast
    • 3.2.3. European Bipolar Depression Addressable Population Forecast
    • 3.2.4. European Schizophrenia Patient Prevalence Forecast
    • 3.2.5. European Schizophrenia Addressable Population Forecast
  • 3.3. China
    • 3.3.1. China Anti-Depressant Drug Market by Value
    • 3.3.2. China Anti-Depressant Drug Market Forecast by Value
    • 3.3.3. China Anti-Psychotic Drug Market by Value
    • 3.3.4. China Anti-Psychotic Drug Market Forecast by Value

4. Market Dynamics

  • 4.1. Key Trends & Developments
    • 4.1.1. Novel Drug Approvals
    • 4.1.2. Rapid Acting Depression Drugs in Development
    • 4.1.3. Direct-to-Customer Advertising
    • 4.1.4. Growing Public Awareness
  • 4.2. Growth Drivers
    • 4.2.1. Increasing Sales of Prescription Drugs
    • 4.2.2. Increased Spending on Medicines
    • 4.2.3. Increased Smoking Prevalence
    • 4.2.4. Rising Spending on Public Health Programs
    • 4.2.5. Rising Global Health Expenditure
    • 4.2.6. Increasing Female Population Worldwide
  • 4.3. Challenges
    • 4.3.1. Patent Expiry
    • 4.3.2. Tough Drug Regulations
    • 4.3.3. Severe Side-Effects

5. Competitive Landscape

  • 5.1. Global Depressive Disorder Market
    • 5.1.1. Revenue Comparison
  • 5.2. Global Anti-Depressants Market
    • 5.2.1. Market Share Comparison
    • 5.2.2. Revenue Comparison
    • 5.2.3. Product Comparison
  • 5.3. Global Anti-Psychtoics Market
    • 5.3.1. Market Share Comparison
    • 5.3.2. Revenue Comparison
    • 5.3.3. Product Comparison

6. Company Profiles

  • 6.1. Pfizer Inc.
    • 6.1.1. Business Overview
    • 6.1.2. Financial Overview
    • 6.1.3. Business Strategies
  • 6.2. AstraZeneca
    • 6.2.1. Business Overview
    • 6.2.2. Financial Overview
    • 6.2.3. Business Strategies
  • 6.3. Eli Lilly and Company
    • 6.3.1. Business Overview
    • 6.3.2. Financial Overview
    • 6.3.3. Business Strategies
  • 6.4. Lundbeck
    • 6.4.1. Business Overview
    • 6.4.2. Financial Overview
    • 6.4.3. Business Strategies

List of Charts

  • Types of Depression
  • Causes & Symptoms of Depression
  • Global Depressive Disorder Market by Value (2010-2015)
  • Global Depressive Disorder Market Forecast by Value (2016-2020)
  • Global Depressive Disorder Market by Region (2015)
  • Global Anti-Depressant Drug Market by Value (2010-2015)
  • Global Anti-Depressant Drug Market Forecast by Value (2016-2020)
  • Global Anti-Psychotic Drug Market by Value (2010-2015)
  • Global Anti-Psychotic Drug Market Forecast by Value (2016-2020)
  • The US Depressive Disorder Market Forecast by Value (2015-2020)
  • The US Mental Health Drug Prescription by Volume (2011-2015)
  • The US Depressive Disorder Patient Prevalence Forecast (2016-2020)
  • The US Bipolar Depression Patient Prevalence Forecast (2016-2020)
  • The US Bipolar Depression Addressable Population Forecast (2016-2020)
  • The US Schizophrenia Patient Prevalence Forecast (2016-2020)
  • The US Schizophrenia Addressable Population Forecast (2016-2020)
  • European Depression Disorder Market Forecast by Value (2015-2020)
  • European Bipolar Depression Patient Prevalence Forecast (2016-2020)
  • European Bipolar Depression Addressable Population Forecast (2016-2020)
  • European Schizophrenia Patient Prevalence Forecast (2016-2020)
  • European Schizophrenia Addressable Population Forecast (2016-2020)
  • China Anti-Depressant Drug Market by Value (2010-2015)
  • China Anti-Depressant Drug Market Forecast by Value (2016-2020)
  • China Anti-Psychotic Drug Market by Value (2010-2015)
  • China Anti-Psychotic Drug Market Forecast by Value (2016-2020)
  • Increasing Sales of Prescription Drugs (2010-2015)
  • Global Spending on Medicines (2010-2020E)
  • Total Spending on Medicines in the US (2010-2015)
  • Global Cigarette Consumption (1940-2015)
  • Global Healthcare Expenditure (2009-2015)
  • Global Female Population (2010-2015)
  • Global Depressive Disorder Market Revenue Comparison (2015)
  • Global Anti-Depressant Market Share by Drugs (2015)
  • Global Anti-Depressant Drug Revenue Comparison (2018)
  • Global Anti-Psychotic Market Share by Drugs (2015)
  • Global Anti-Psychotic Drug Revenue Comparison (2020)
  • Pfizer Inc. Revenue by Segment (2015)
  • Pfizer Inc. Revenue and Net Income (2012-2015)
  • AstraZeneca Revenue by Segment (2015)
  • AstraZeneca's Revenue (2012-2015)
  • Eli Lilly Revenue Share by Segments (2015)
  • Eli Lilly Revenue and Net Income (2011-2015)
  • Lundbeck's Key Therapeutic Areas (2015)
  • Lundbeck's Revenue Share by Products (2015)
  • Lundbeck's Revenue and Net Income (2011-2015)
  • Lundbeck's Research & Development Expenses (2011-2015)

List of Tables

  • Novel Drug Approvals for Depression Disorder (2015)
  • Major Rapid Acting Depression Drugs in Development (2015)
  • Severe Side-Effects of Depression Disorder Drugs
  • Global Anti-Depressants Market Comparison by Product Profile (2015)
  • Global Anti-Psychotics Market Comparison by Product Profile (2015)
  • New Products of Pfizer with FDA Approval (2015/2016)
  • Approvals and Upcoming Drugs (2015)
  • Lundbeck's New Drugs in Development (2015)
Back to Top